The importance of type I IFN in SLE pathogenesis and its potential as target for treatment was highlighted by the approval of anifrolumab, a type 1 interferon receptor (IFNAR1) antagonist in 2021 (Burki, 2021). Here, IFNAR1 is linked to systemic lupus erythematosus.